Prognostic impact of human epidermal growth factor-2 (HER2) status on overall survival (OS) of advanced gastric cancer (AGC) patients (pts) treated with standard chemotherapy without trastuzumab as a first-line treatment: A Japanese multicenter collaborative retrospective study.
Tomohiro Nishina
No relevant relationships to disclose
Nozomu Fuse
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Taiho Pharmaceutical
Takeshi Kuwata
No relevant relationships to disclose
Shigenori Kadowaki
No relevant relationships to disclose
Eiji Shinozaki
No relevant relationships to disclose
Nozomu Machida
No relevant relationships to disclose
Satoshi Yuki
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
Akira Ooki
No relevant relationships to disclose
Shinya Kajiura
No relevant relationships to disclose
Takahiro Goji
No relevant relationships to disclose
Takeharu Yamanaka
No relevant relationships to disclose
Takahide Sasaki
No relevant relationships to disclose
Kohei Shitara
No relevant relationships to disclose
Yasutoshi Kuboki
No relevant relationships to disclose
Takayuki Yoshino
Consultant or Advisory Role - Takeda
Honoraria - Bayer; Daiichi Sankyo; ImClone Systems; Taiho Pharmaceutical
Research Funding - Bayer; Daiichi Sankyo; ImClone Systems; Taiho Pharmaceutical
Atsushi Ochiai
No relevant relationships to disclose
Atsushi Ohtsu
Stock Ownership - Chugai Pharma; Roche; Taiho Pharmaceutical